The Potential of Academic Drug Discovery: Successes and Challenges

1. Introduction

Academic Drug Discovery Centers (ADDCs) have become increasingly central to the development of new therapeutics, underscoring the growing role of universities in translational research [1], which is the process of turning basic scientific discoveries into practical applications that improve human health. Over the past three decades, these centers have expanded significantly in both number and impact, leveraging government funding, philanthropic support, and industry collaborations to advance numerous compounds into clinical trials and even FDA approval [2,3]. As of the most recent count by the Academic Drug Discovery Consortium, there are at least 76 ADDCs in the United States, 15 in Europe, 4 in the Middle East, and 3 in Australia [4]. However, these figures likely underrepresent the true global footprint, as many centers—particularly in China (e.g., Shanghai Institute of Materia Medica), India (e.g., The Council of Scientific and Industrial Research Institute) and other emerging regions—are not accounted for.

In the U.S., academic institutions are playing an increasingly vital role in drug discovery. A 2023 JAMA study found that NIH-supported drugs with novel targets received an average investment of $1.44 billion per approval—on par with private industry [5]. While these funds support academia and biotech, ADDCs are also major beneficiaries. It is also noteworthy that NIH funding has been critical for drug development in the United States. NIH funding contributed to developing nearly every FDA-approved new molecular entity from 2010 to 2019, with documented support for the drug’s identification or mechanistic basis in 354 of 356 products (99.4%) approved from 2010–2019 [5,6].

Industry-academia collaborations have also evolved into more strategic and multifaceted partnerships [7]. As drug development becomes more complex and costly, pharmaceutical companies are increasingly turning to academic researchers in the early stages of R&D to share risk and tap into emerging technologies. A 2022 report from the Association of the British Pharmaceutical Industry highlighted this trend, documenting 2,687 industry-academic collaborations in the UK—more than double the 1,134 collaborations reported in 2013 [8]. These partnerships now span a wide range of activities, from target validation and genetic engineering to analytical method development, process optimization, and clinical trial design. This reflects a broader shift in the pharmaceutical landscape, as companies increasingly outsource early-stage R&D once done entirely in-house.

Simultaneously, the technological and therapeutic landscape continues to evolve at a rapid pace [9]. Innovations in big data, artificial intelligence, bioinformatics, and human-derived models such as induced pluripotent stem cells (iPSCs) and organoids are transforming the speed and precision of drug discovery. To remain competitive and relevant, ADDCs must adopt these emerging technologies and navigate a range of ongoing challenges—from fluctuations in government funding and the need for specialized industry expertise to the intricacies of intellectual property and commercialization strategies [10].

In this editorial, we explore the key drivers behind the success of ADDCs, highlight leading centers, and examine the challenges and opportunities shaping the future of academic drug discovery.

2. Hallmarks of Success

Several Academic Drug Discovery Centers (ADDCs) have successfully advanced therapeutic candidates into clinical trials, providing compelling evidence that academic institutions can function as effective engines of drug discovery [1,11]. We have highlighted selected examples of medicines developed in academic drug discovery centers in Table 1. While all ADDCs face funding constraints, commercialization hurdles, and competition from industry, many have found ways to thrive. The most successful centers share key traits that enable them to translate discoveries into clinical therapies. These include:

Table 1:

Examples of Medicines Discovered by Academia

Drug Discovery Center	University	Therapeutic	Type	Indication	Stage
Calibr	Scripps Research Institute	Avivertinib FTX-6058 CLB001+SWI019 Ganaplacide (KAF156)	SM SM CAR-T SM	NSCLC Sickle cell B-cell malignancies Malaria	Phase 3 (withdrawn) Phase 1b Phase 1 Phase 3
Center for Cellular Immunotherapies (Carl June)	University of Pennsylvania	Kymriah	CAR-T	B-cell lymphomas	FDA approved
Center for Integrative Chemical Biology and Drug Discovery	University of North Carolina	MRX2843	SM	AML, NSCLC	Phase 1 (complete)
Drug Discovery Unit	University of Dundee	M5717 (cabamiquine) PCLX-001 (zelenirstat)	SM SM	Malaria NHL, mCRC	Phase 2 Phase 2a
Emory Institute for Drug Development	Emory University	Epivir (lamivudine) Emtriva (emtricitabine) EIDD-2801(molnupiravir)	SM SM SM	HIV, HBV HIV COVID-19	FDA approved FDA approved FDA emergency use
High Throughput Screening Center	University of Texas Southwestern	Belzutifan (Welireg) DSM265	SM SM	VHL disease Malaria	FDA approved Phase 2 (complete)
Holistic Drug Discovery and Development Center (H3D)	University of Cape Town	MMV390048	SM	Malaria	Phase 2a (complete)
Johns Hopkins Drug Discovery	Johns Hopkins University	DRP-104 SCD-153 JHU-2545	SM SM SM	Solid tumors Alopecia areata Prostate cancer	Phase 1/2a Phase 1 Pre-clinical
MD Andersen Cancer Center	University of Texas	Loncastuximab tesirine CT-0508 BP1001 (prexigebersen)	mAb CAR-T ASO	B-cell lymphoma HC AML, CML	FDA approved Phase 1 / Fast Track Phase 2a
Sanford Burnham Prebys Medical Discovery Institute	Sanford Burnham Prebys	CEND-1 (iRGD) DS-1211	Peptide SM	Pancreatic cancer PXE	Phase 1b/2a Phase 2
Tri-Institutional Therapeutics Discovery Institute	Memorial Sloan Kettering Cancer Center, Rockefeller, Weill Cornell Medicine	SBS-1000 CB-012 CD371 Not-disclosed	SM mAB mAb SM	Pain AML AML Contraception	Phase 1 (complete) Phase 1 Phase 1 Preparing IND
Warran Center for Neuroscience Drug Discovery	Vanderbilt University	VU319	SM	Alzheimer’s disease	Phase 1 (complete)

Acute myeloid leukemia (AML), Antisense oligonucleotide (ASO), Chimeric antigen receptor T-cell therapy (CAR-T), Chronic myelogenous leukemia (CML), Hepatocellular carcinoma (HC), Human immunodeficiency virus (HIV), Hepatitis B virus (HBV), Metastatic colorectal cancer (mCRC), Monoclonal antibody (mAb), Non-Hodgkin Lymphoma (NHL), Non-small cell lung cancer (NSCLC), Pseudoxanthoma elasticum (PXE), Small-molecule (SM) Spinal muscular atrophy (SMA), von Hippel-Lindau (VHL)

2.1. Sustainable and Diverse Funding Sources

Successful ADDCs establish multiple funding streams beyond the typical academic NIH and DOD grants to ensure long-term viability. They also pursue funding with disease-focused foundations and commercially oriented SBIR/STTR grants. Partnerships with pharmaceutical companies and investors provide financial support and access to industry expertise, while philanthropic donations and grants from disease foundations further enhance financial security [7,8]. This diversified funding model allows centers to pursue high-risk, high-reward projects while maintaining operational flexibility.

2.2. Strategic Project Selection with a Focus on Commercial Potential

Successful ADDCs prioritize projects with clear industry relevance, commercialization potential, and alignment with their strategic goals [3]. Although universities often offer ADDCs projects from basic research labs, selective evaluation is crucial. By focusing on projects with a well-defined path to clinical impact and market adoption, ADDCs increase their likelihood of translating early-stage discoveries into viable therapeutics.

2.3. Focused Collaboration that Leverages the Unique Expertise of ADDCs

Collaboration is a cornerstone of success for Academic Drug Discovery Centers. The most productive partnerships strategically align the disease-specific expertise of academic investigators with the specialized capabilities of ADDCs. Centers that maintain a clear focus on their core strengths—without attempting to duplicate or compete with their collaborators’ domain knowledge—are more likely to achieve translational impact [12] (i.e., produce a measurable research contribution that advances a scientific discovery into clinical development, ultimately enabling new therapies to reach patients). Within this framework, ADDCs often operate in a disease-agnostic manner, enabling them to apply their technical expertise across a broad spectrum of therapeutic areas. Notably, transactional or fee-for-service models rarely result in successful outcomes; such arrangements typically lack the mutual investment, shared goals, and iterative communication that define a truly collaborative relationship.

2.4. Niche Specialization to Address Unmet Needs

Some successful ADDCs focus on therapeutic areas underserved by the pharmaceutical industry, such as neglected tropical diseases and rare (or orphan) genetic disorders. For example, The Calibr-Skaggs Institute for Innovative Medicines at Scripps Research has pursued the development of novel antimalarial therapies. This effort led to the discovery of ganaplacide (KAF156), the most advanced non-artemisinin antimalarial compound. KAF156 is currently in a Phase 3 clinical trial [13]. Another example is the Cold Spring Harbor Laboratory, which pioneered the discovery of antisense oligonucleotides for spinal muscular atrophy [14]. In partnership with Ionis Pharmaceuticals, this work led to the FDA approval of Nusinersen (Spinraza) in 2016. By focusing on unmet medical needs, ADDCs can establish a distinct and impactful niche.

2.5. Comprehensive Drug Development Infrastructure

Successful ADDCs can either build in-house capabilities or form strategic collaborations to support essential drug development functions, including assay development, computational science, structural biology, medicinal chemistry, and drug metabolism and pharmacokinetics [3]. Access to high-throughput screening, in vivo disease models, human iPSC and organoid testing platforms, as well as robust data analytics, further accelerates drug discovery, ensuring that promising compounds do not stall due to a lack of critical expertise and resources.

2.6. Supportive University and Regional Ecosystem

ADDCs thrive when universities actively support translational research and are within strong biotech and pharmaceutical hubs [15]. Proximity—or at least access—to biopharma leadership, venture capital, and angel investors is also essential, as it facilitates networking, investment, and risk reduction for early-stage projects. Regional biotech clusters can also be crucial, as access to funding and regulatory expertise can significantly expedite commercialization [15].

2.7. Integration of Non-Scientific Industry Expertise

Beyond scientific innovation, expertise in regulatory affairs, project management, clinical development, fundraising, and market analysis is essential [3]. Without these capabilities, even the most promising drug candidates may struggle to attract investment or navigate challenging regulatory pathways. ADDCs integrating these non-scientific functions early in the process are more likely to transition discoveries into successful clinical programs [12,16].

2.8. Adoption of Emerging Technologies

ADDCs that incorporate cutting-edge technologies—such as AI-driven drug discovery, gene editing, human organ-on-a-chip, 3D human cell culture systems, cheminformatics, and advanced screening techniques—gain a competitive edge [9,17]. Many of these innovations originate within research universities or small start-ups from universities, allowing ADDCs to pioneer their application in the drug discovery pipeline before they are widely adopted by industry.

The most impactful ADDCs operate with the efficiency and focus of biotech startups. This includes rapidly terminating failing projects or pivoting to new directions rather than persisting with unpromising programs. Tighter budgets and clearly defined go/no-go criteria support this agility, as does the intuition that comes from having seasoned drug discovery scientists with decades of experience—something recent graduates may lack. The ability of ADDCs to secure diverse funding sources, foster interdisciplinary collaboration, specialize in underserved therapeutic areas, and adopt cutting-edge technologies ensures they remain at the forefront of drug discovery.

3. The Challenges Faced by ADDCs

ADDCs face unique challenges as they attempt to bridge the gap between basic research and developing viable therapeutic candidates. One of the most pressing issues is funding. Unlike pharmaceutical companies with significant R&D budgets (planned years in advance), ADDCs must rely on a mix of government and/or disease foundation grants, philanthropic donations, and industry partnerships to sustain their operations. Funding in the U.S. is undergoing rapid change, with shifts in government priorities and policies affecting the availability of research dollars [18]. To ensure long-term viability, ADDCs must continue to broaden and diversify their revenue streams. This includes deepening strategic partnerships with pharmaceutical companies and philanthropic organizations, securing venture capital investment, and actively pursuing translational funding opportunities offered by disease-focused foundations. Emerging funding models—such as crowdfunding initiatives and open-source drug discovery platforms—also present novel avenues for resource generation [19].

ADDCs must continue to adapt to a rapidly evolving therapeutic landscape. Advances in genetic medicine, biologics, and gene therapies are reshaping drug discovery, with innovations like antisense oligonucleotides, mRNA vaccines, and gene therapies often emerging from individual academic labs—without the need for large-scale infrastructure [17]. These therapeutics often target a broader portion of the genome than small-molecules or antibodies, which are limited to less than 1% of druggable targets [17]. In response, many ADDCs have expanded beyond traditional small-molecule discovery and are now pursuing cell-based therapies, gene therapies, RNA therapeutics, nanomedicine, PROTACS, and protein and peptide-based therapies [1].

Another critical challenge is establishing a competitive advantage in a crowded, resource-intensive field. Simply mirroring pharmaceutical companies on a smaller scale is not sustainable. ADDCs must, therefore, differentiate themselves by targeting diseases with limited commercial appeal, leveraging innovative discovery platforms, or pursuing high-risk projects avoided by the industry. Additionally, academic institutions often face inertia, with NIH funding (e.g., R01 grants) encouraging prolonged work on the same projects even if this is likely not to lead to a commercial product. This is unlike industry counterparts, who need to swiftly reallocate resources from unpromising initiatives. Small business milestone-driven grants with shorter funding terms may assist with critical decision-making. To survive, ADDCs must rigorously assess project progress and pivot promptly to prevent wasting limited resources.

Partnerships between private companies and ADDCs are vital for translational drug discovery but can sometimes be complicated by differing cultures, priorities, and incentives. Issues can include IP disputes, misaligned timelines, and conflicting goals—academia values publication, while industry prioritizes speed and commercialization. ADDCs help bridge this gap by incorporating industry-experienced professionals who can anticipate and manage these challenges. Clear agreements on IP, data sharing, and milestones, along with open communication, help align expectations and build trust, enabling ADDCs to combine academic innovation with industrial rigor.

Finally, ADDCs often lack internal commercial expertise, which limits their ability to attract external investment and translate discoveries into market-ready therapeutics. Unlike biotech startups, which are purpose-built for commercialization, academic centers typically rely on principal investigators securing government funding rather than experienced business development professionals skilled in engaging investors. Moreover, ADDCs must navigate diverse stakeholder expectations, balancing the university’s mission to educate scientists and publish research with the need to protect intellectual property. Successfully managing these competing priorities requires strong scientific leadership, strategic planning, and a flexible operational model that supports both innovation and financial sustainability. Identifying scientists with a balanced understanding of both the scientific and business aspects of drug development is critical to the long-term success of ADDCs.

4. What are the future opportunities for ADDCs?

ADDCs are well-positioned to leverage emerging technologies, foster global collaborations, and adopt innovative funding models to expand their impact. Amongst the most transformative tools is likely to be artificial intelligence (AI), which has been proposed to accelerate drug discovery by optimizing target selection, predicting drug interactions, and analyzing complex datasets [20,21]. The current exuberance around AI suggests we are at the point of commoditization of some of these technologies. Coupling generative design with synthesizing and testing identified compounds in vitro could be a valuable edge for ADDCs. Technologies for automated laboratories with a focus on drug discovery may also facilitate this as well. Informatics and -omics technologies have all been developing over the past decade, creating massive datasets that can also enable more precise identification and characterization of drug targets [9].

Advances in stem cell biology have enabled the development of human-relevant disease models, such as human organoids, microphysiological systems, and ex vivo cultures, which offer improved predictive power over traditional animal models [22]. Innovations in automated synthesis and high-throughput computational chemistry are improving the speed, diversity and cost-efficiency of medicinal chemistry. Incorporating online tools that use machine learning to predict molecular properties, drug metabolism, and toxicity are becoming routine. At the same time, high-throughput computational chemistry and continuous flow synthetic platforms provide more efficient routes to molecules and their analogs—making synthesis and structure-activity relationship studies faster and data-driven [23].

Beyond technological advancements, collaborations between academia and pharmaceutical companies are evolving, becoming more sophisticated and multidimensional [8]. Opportunities now include early-stage, multi-stakeholder consortia employing open-source strategies and R&D networks that span disciplines and geographies. Public-private partnerships are also expanding to include for-profit companies, non-profit organizations, academic institutions, and even patient-driven crowdsourcing communities—collectively advancing drug development in new and inclusive ways [11,16,24].

ADDCs are well-positioned to benefit from open science, which promotes transparency and collaboration through unrestricted sharing of data, methods, and materials. By providing access to compound libraries, assays, and expertise, open science accelerates innovation, reduces costs, and broadens drug discovery in resource-limited settings. Examples include the Structural Genomics Consortium (SGC), which shares chemical probes without IP restrictions, and the Drugs for Neglected Diseases initiative (DNDi), which uses open models to develop therapies for underserved diseases.

Finally, innovative funding models will reshape how ADDCs sustain their research. While government grants remain essential, many centers increasingly turn to alternative sources, especially in the current funding environment. Disease-specific foundations—such as the Michael J. Fox Foundation (Parkinson’s disease), the Bill & Melinda Gates Foundation (neglected tropical diseases), and the Cystic Fibrosis Foundation—have funded academic drug development efforts. Accelerator programs like the Critical Path Institute’s Translational Therapeutics Accelerator (TRxA) and Thermo Fisher Scientific’s Accelerator^™ Drug Development also directly support university-based drug discovery. Although there is limited data on the total investment from pharmaceutical companies into academic drug discovery, there is growing evidence of increased collaboration and geographic proximity between industry and academic centers [8]. Finally, venture capital and venture philanthropy organizations—such as the Alzheimer’s Drug Discovery Fund, Thiel Foundation, Chan-Zuckerberg Foundation and many others—are potential funding sources. Funding diversification is paramount to help reduce dependence on traditional funding mechanisms while promoting long-term sustainability and continued investment in translational research.

5. Expert Opinion

From our experience, the future of ADDCs hinges on diversification—both in funding sources and in the strategies employed to drive translational drug discovery. Over the years, we have built a sustainable model by combining diverse funding streams, integrating academic and industry expertise, embracing emerging technologies, and cultivating collaborative partners and projects.

We have found that ADDCs play a crucial role in overcoming bottlenecks that can hinder drug development. Our own work shows that stalled projects—whether due to pharmacokinetic limitations, challenges with blood-brain barrier penetration, or failure in initial clinical indications—can be revitalized through the application of a diverse array of emerging technologies. For example, dendrimer-based delivery systems have enabled targeted distribution of therapeutics to the CNS, overcoming blood-brain barrier limitations. We have used this platform to deliver otherwise non-penetrant drugs, such as GCPII and nSMase2 inhibitors, directly to glial cells [25,26].

We have also found that our academic freedom empowers us to pursue high-risk, high-reward ideas with transformative potential. For example, we resurrected the glutamine antagonist 6-diazo-5-oxo-L-norleucine (DON), which was a promising anticancer therapeutic but had previously failed to advance clinically due to gastrointestinal toxicity. While pharmaceutical companies and investors had lost interest in DON, we successfully developed prodrugs that overcame these toxicity issues, and one is now in Phase 1/2a clinical trials [27]. This example illustrates that with deep expertise in medicinal chemistry and disease biology, academic institutions are uniquely positioned to give new life to challenging therapeutic targets or identify novel targets and mechanisms that pharmaceutical companies may overlook. ADDCs are also free from the immediate, intense pressures of profitability, so they can effectively de-risk both targets and explore novel indications. For example, our focus on neurological drug targets, which are often deemed risky because of their translational challenges, has provided a competitive advantage for our group and led to unexpected therapeutic opportunities in non-CNS diseases [28,29].

One of the key advantages of conducting drug discovery in an academic setting is the unparalleled access to cutting-edge technologies, clinical data, and newly identified therapeutic targets. ADDCs are usually uniquely geographically positioned near basic research laboratories, hospitals, and clinical collaborators—resources that are often less readily available to pharmaceutical or biotech companies. For example, when we identified a novel target for inflammatory bowel disease, we collaborated with the clinical GI department at Johns Hopkins and obtained de-identified patient samples to test our hypothesis within just a few weeks. That would be nearly impossible to do in a biopharma. We also benefit from access to extensive clinical datasets generated within the hospital systems. These collaborations with researchers who collect and analyze clinical data allow us to efficiently leverage real-world evidence in support of our drug development efforts.

Sustaining this role requires strong internal and external collaboration. Innovative approaches in medicinal chemistry and large-scale data-driven discovery demand significant, costly resources and expertise—challenges we cannot tackle alone. To advance our drug discovery efforts, we have built partnerships within our university, with biotech and pharmaceutical companies, and with international collaborators.

We have also attempted to capitalize on recent technological advances in earnest to remain competitive. To optimize the chemistry of promising lead compounds, we have begun incorporating AI, and computational drug development tools to screen large compound libraries. These technologies are still in their infancy, and while they cannot replace traditional HTS and synthesis platforms, they do provide additional tools to complement existing technologies. In parallel, we have been exploring emerging drug delivery technologies—such as antisense oligonucleotides—to enhance our strength in small-molecule drug discovery.

Finally, the broader biomedical research landscape in the U.S. remains in flux. Policy shifts, changing federal research priorities, and evolving government funding structures will continue to shape the future of academic medicine. For example, the Trump administration’s 2026 budget proposal includes a 40% cut to NIH funding, which, if enacted by Congress, would significantly impact U.S. biomedical research [18]. But ADDCs have an advantage over basic science academic laboratories given their diversified funding sources. This flexibility allows them to adapt to continual political and economic shifts—whether by pursuing public-sector funding or forming closer ties with philanthropic organizations or private-sector partners funding sources.

The need for novel therapeutics remains immense, and ADDCs are uniquely equipped to bridge critical gaps that industry cannot fill on its own. In conclusion, in the years ahead, ADDCs that combine technological agility with financial resilience and strategic collaboration will be best positioned to thrive.